Avantor (NYSE:AVTR) PT Raised to $27.00 at Robert W. Baird

Avantor (NYSE:AVTR) had its target price boosted by equities research analysts at Robert W. Baird from $26.00 to $27.00 in a research note issued to investors on Monday, Benzinga reports. The firm presently has an “outperform” rating on the stock. Robert W. Baird’s price objective would indicate a potential downside of 2.35% from the company’s current price.

Other research analysts have also recently issued research reports about the company. Barclays cut their price objective on Avantor from $28.00 to $25.00 and set an “overweight” rating on the stock in a research report on Friday, June 28th. Evercore ISI cut their price objective on Avantor from $28.00 to $27.00 and set an “outperform” rating on the stock in a research report on Tuesday, July 2nd. Citigroup cut Avantor from a “buy” rating to a “neutral” rating and cut their price objective for the stock from $30.00 to $23.00 in a research report on Wednesday, July 10th. Royal Bank of Canada boosted their price objective on Avantor from $30.00 to $31.00 and gave the stock an “outperform” rating in a research report on Monday, July 15th. Finally, Deutsche Bank Aktiengesellschaft boosted their price objective on Avantor from $23.00 to $25.00 and gave the stock a “hold” rating in a research report on Thursday, April 18th. Five investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $27.21.

Avantor Stock Up 5.3 %

Shares of NYSE:AVTR opened at $27.65 on Monday. The stock has a market cap of $18.78 billion, a price-to-earnings ratio of 70.90, a PEG ratio of 2.63 and a beta of 1.32. The company has a quick ratio of 1.05, a current ratio of 1.61 and a debt-to-equity ratio of 0.94. Avantor has a 12-month low of $16.63 and a 12-month high of $27.66. The business’s 50 day moving average is $22.47 and its 200 day moving average is $23.71.

Insider Buying and Selling

In other news, insider Christophe Couturier 10,000 shares of Avantor stock in a transaction on Tuesday, July 30th. The was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.50% of the stock is currently owned by insiders.

Institutional Trading of Avantor

A number of institutional investors have recently added to or reduced their stakes in the stock. Versant Capital Management Inc raised its holdings in shares of Avantor by 2,003.6% in the 2nd quarter. Versant Capital Management Inc now owns 1,157 shares of the company’s stock valued at $25,000 after acquiring an additional 1,102 shares in the last quarter. Fifth Third Bancorp raised its holdings in shares of Avantor by 125.3% in the 4th quarter. Fifth Third Bancorp now owns 1,248 shares of the company’s stock valued at $28,000 after acquiring an additional 694 shares in the last quarter. Livforsakringsbolaget Skandia Omsesidigt raised its holdings in shares of Avantor by 565.5% in the 4th quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 1,331 shares of the company’s stock valued at $30,000 after acquiring an additional 1,131 shares in the last quarter. Blue Trust Inc. raised its holdings in shares of Avantor by 1,830.3% in the 2nd quarter. Blue Trust Inc. now owns 1,467 shares of the company’s stock valued at $31,000 after acquiring an additional 1,391 shares in the last quarter. Finally, Gladius Capital Management LP purchased a new stake in shares of Avantor in the 4th quarter valued at about $42,000. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Avantor Company Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.